After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...

UCB and Biogen (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, or DZP, a novel Fc-free anti-CD40L drug candidate, demonstrating significant ...

(RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant clinical ...

UCB has three products currently in phase III which are due to produce pivotal results in the next few years: brivaracetam for epilepsy, lupus treatment epratuzumab and romosozumab for osteoporosis.

United Commercial Bank PLC has asked 40 senior officials to resign amid allegations of corruption and professional ...

The board of United Community Banks, Inc. ( NYSE:UCB ) has announced that it will pay a dividend of $0.24 per share ...

Mark Bodmer and Jonathan Lewis of UCB pharma talk us though the partnering model at UCB, and how partnering can drive innovation. The world is changing and it’s no different for the ...

Technical analysis for United Community Banks Inc. UCB including support levels resistance levels and stop losses for UCB ...